TMS Co., Ltd. (JP:4891) has released an update. TMS Co., Ltd., a clinical-stage biopharmaceutical company, is making strides with its promising lead program, TMS-007, aimed at treating acute ischemic ...
TMS Co., Ltd. (JP:4891) has released an update. TMS Co., Ltd. has announced the publication of Phase 2a clinical trial results for JX10 (TMS-007), a potential treatment for acute ischemic stroke, in a ...
Use of inhibitory transcranial magnetic stimulation (TMS) over the speech area in the right side of the brain significantly improved language recovery in patients with stroke, new research shows. "The ...
A clinic in Bellevue talks about transcranial magnetic stimulation. The new technology is becoming more widely available to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback